Get in touch with one of our Xperts.
The EMA glossary defines a biological marker, or biomarker, as ‘an objective and quantifiable measure of a physiological process, pathological process or response to a treatment (excluding measurements of how an individual feels or functions)’. Similarly, the FDA defines a biomarker as ‘a defined characteristic that is measured as an indicator of normal biological processes, continue reading…
Drug development is a daunting and difficult task where all the puzzle pieces need to click to result in an efficacious and safe treatment for patients. It is a high-risk endeavor involving many different scientific and non-scientific disciplines over a long period of time. The current estimates to develop a drug are about 2.3 continue reading…
Drug repurposing, also called drug repositioning, reprofiling or retasking, is the process of identifying a new use for an existing medicine/active substance outside the scope of the original indication(s). It includes new therapeutic uses for existing medicines, different formulations of the same medicine, and/or creating new combinations of medicines or medicines with medical devices[1]. Drug continue reading…
Inez de Greef elected as fellow of the Netherlands Academy of Engineering We are thrilled to announce that Inez de Greef, CEO of Treeway and co-founder and Managing Partner of 3D-PharmXchange, has been elected as a fellow of the Netherlands Academy of Engineering (NAE). The NAE brings together top experts in technological sciences and applied continue reading…
© 3D-PharmXchange 2024